The treatment of glucocorticoid-induced osteoporosis

Journal of Steroid Biochemistry and Molecular Biology

Volumn 88, Issue 4-5, 2004, Pages 337-349

  Cohen, Dana ^a   Adachi, Jonathan D ^a  

^a NONE   (Canada)

Author keywords

Glucocorticoids; Osteoporosis; Treatment

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCITRIOL; CALCIUM; CLODRONIC ACID; ESTRADIOL; ETIDRONIC ACID; FLUORIDE; GLUCOCORTICOID; NANDROLONE; NORETHISTERONE; PAMIDRONIC ACID; PARATHYROID HORMONE; RISEDRONIC ACID; TESTOSTERONE; VITAMIN D;

ALCOHOL ABSTINENCE; BEHAVIOR MODIFICATION; BONE DENSITY; BONE MASS; ESTROGEN THERAPY; EXERCISE; FRACTURE; HORMONE SUBSTITUTION; HUMAN; OSTEOPOROSIS; PRACTICE GUIDELINE; REVIEW; RISK; RISK REDUCTION; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 2442427726     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2004.01.003     Document Type: Article

References (76)

1. Saag K.G., Koehnke R., Caldwell J.R., Brasington R., Burmeister L.F., Zimmerman B., et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am. J. Med. 96:1994;115-123
2. Lukert B.P., Raisz L.G. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann. Intern. Med. 112:1990;352-364
3. Van Staa T.P., Leufkens H.G., Abenhaim L., Zhang B., Cooper C. Use of oral corticosteroids and risk of fractures. J. Bone Miner. Res. 15:2000;993-1000
4. Van Staa T.P., Leufkens H.G., Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos. Int. 13:2002;777-787
5. Van Staa T.P., Leufkens H.G., Abenhaim L., Begaud B., Zhang B., Cooper C. Use of oral corticosteroids in the United Kingdom. QJM. 93:2000;105-111
6. Adachi J.D., Bensen W.G., Bianchi F., Cividino A., Pillersdorf S., Sebaldt R.J., et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year follow-up. J. Rheumatol. 23:1996;995-1000
7. Adinoff A.D., Hollister J.R. Steroid-induced fractures and bone loss in patients with asthma. N. Engl. J. Med. 309:1983;265-268
8. Hahn T.J., Boisseau V.C., Avioli L.V. Effect of chronic corticosteroid administration on diaphyseal and metaphyseal bone mass. J. Clin. Endocrinol. Metab. 39:1974;274-282
9. Van Staa T.P., Leufkens H.G., Cooper C. Use of inhaled corticosteroids and risk of fractures. J. Bone Miner. Res. 16:2001;581-588
10. McEvoy C.E., Ensrud K.E., Bender E., Genant H.K., Yu W., Griffith J.M., et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care. Med. 157:1998;704-709
11. Kroger H., Honkanen R., Saarikoski S., Alhava E. Decreased axial bone mineral density in pre-menopausal women with rheumatoid arthritis: a population based study. Ann. Rheum. Dis. 53:1994;18-23
12. Reid I.R. Steroid-induced osteoporosis. Osteoporos. Int. 7(Suppl. 3):1997;S213-S216
13. Pearce G., Tabensky D.A., Delmas P.D., Baker H.W., Seeman E. Corticosteroid-induced bone loss in men. J. Clin. Endocrinol. Metab. 83:1998;801-806
14. Patschan D., Loddenkemper K., Buttgereit F. Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone. 29:2001;498-505
15. Luppen C.A., Smith E., Spevak L., Boskey A.L., Frenkel B. Bone morphogenetic protein-2 restores mineralization in glucocorticoid-inhibited MC3T3-E1 osteoblast cultures. J. Bone Miner. Res. 18:2003;1186-1197
16. Manolagas S.C., Weinstein R.S. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J. Bone Miner. Res. 14:1999;1061-1066
17. Weinstein R.S., Jilka R.L., Parfitt A.M., Manolagas S.C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 102:1998;274-282
18. Weinstein R.S., Chen J.R., Powers C.C., Stewart S.A., Landes R.D., Bellido T., et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J. Clin. Invest. 109:2002;1041-1048
19. Sakakura M., Takebe K., Nakagawa S. Inhibition of luteinizing hormone secretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects. J. Clin. Endocrinol. Metab. 40:1975;774-779
20. Hsueh A.J., Erickson G.F. Glucocorticoid inhibition of FSH-induced estrogen production in cultured rat granulosa cells. Steroids. 32:1978;639-648
21. Doerr P., Pirke K.M. Cortisol-induced suppression of plasma testosterone in normal adult males. J. Clin. Endocrinol. Metab. 43:1976;622-629
22. Jilka R.L., Hangoc G., Girasole G., Passeri G., Williams D.C., Abrams J.S., et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 257:1992;88-91
23. Yeap S.S., Hosking D.J. Management of corticosteroid-induced osteoporosis. Rheumatol. Oxford. 41:2002;1088-1094
24. Plotkin L.I., Weinstein R.S., Parfitt A.M., Roberson P.K., Manolagas S.C., Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J. Clin. Invest. 104:1999;1363-1374
25. Amin S., LaValley M.P., Simms R.W., Felson D.T. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J. Bone Miner. Res. 17:2002;1512-1526
26. Adachi J.D., Bensen W.G., Brown J., Hanley D., Hodsman A., Josse R., et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N. Engl. J. Med. 337:1997;382-387
27. Adachi J.D., Saag K.G., Delmas P.D., Liberman U.A., Emkey R.D., Seeman E., et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 44:2001;202-211
28. Saag K.G., Emkey R., Schnitzer T.J., Brown J.P., Hawkins F., Goemaere S., et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced osteoporosis intervention study group. N. Engl. J. Med. 339:1998;292-299
29. Reid D.M., Hughes R.A., Laan R.F., Sacco-Gibson N.A., Wenderoth D.H., Adami S., et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European corticosteroid-induced osteoporosis treatment study. J. Bone Miner. Res. 15:2000;1006-1013
30. Cohen S., Levy R.M., Keller M., Boling E., Emkey R.D., Greenwald M., et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 42:1999;2309-2318
31. Gonnelli S., Rottoli P., Cepollaro C., Pondrelli C., Cappiello V., Vagliasindi M., et al. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif. Tissue Int. 61:1997;382-385
32. Roux C., Oriente P., Laan R., Hughes R.A., Ittner J., Goemaere S., et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos study group. J. Clin. Endocrinol. Metab. 83:1998;1128-1133
33. Skingle S.J., Crisp A.J. Increased bone density in patients on steroids with etidronate. Lancet. 344:1994;543-544
34. Mulder H., Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br. J. Rheumatol. 33:1994;348-350
35. Brown J.P., Olszynski W.P., Hodsman A., Bensen W.G., Tenenhouse A., Anastassiades T.P., et al. Positive effect of etidronate therapy is maintained after drug is terminated in patients using corticosteroids. J. Clin. Densitom. 4:2001;363-371
36. Boutsen Y., Jamart J., Esselinckx W., Devogelaer J.P. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J. Bone Miner. Res. 16:2001;104-112
37. Pitt P., Li F., Todd P., Webber D., Pack S., Moniz C. A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment. Thorax. 53:1998;351-356
38. Geusens P., Dequeker J., Vanhoof J., Stalmans R., Boonen S., Joly J., et al. Cyclical etidronate increases bone density in the spine and hip of post-menopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. Ann. Rheum. Dis. 57:1998;724-727
39. Reid I.R., King A.R., Alexander C.J., Ibbertson H.K. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD). Lancet. 1:1988;143-146
40. Frediani B., Falsetti P., Baldi F., Acciai C., Filippou G., Marcolongo R. Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound. Bone. 33:2003;575-581
41. Buckley L.M., Hillner B.E. A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids. J. Rheumatol. 30:2003;132-138
42. Solomon D.H., Kuntz K.M. Should post-menopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? a cost-effectiveness analysis. Arthritis Rheum. 43:2000;1967-1975
43. Cummings S.R., Browner W.S., Bauer D., Stone K., Ensrud K., Jamal S., et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of osteoporotic fractures research group. N. Engl. J. Med. 339:1998;733-738
44. Lukert B.P., Johnson B.E., Robinson R.G. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J. Bone Miner. Res. 7:1992;1063-1069
45. Hall G.M., Daniels M., Doyle D.V., Spector T.D. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum. 37:1994;1499-1505
46. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the women's health initiative randomized controlled trial. JAMA. 288:2002;321-333
47. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. Heart and estrogen/progestin replacement study (HERS) research group. JAMA. 280:1998;605-613
48. Hulley S., Furberg C., Barrett-Connor E., Cauley J., Grady D., Haskell W., et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA. 288:2002;58-66
49. Grady D., Herrington D., Bittner V., Blumenthal R., Davidson M., Hlatky M., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA. 288:2002;49-57
50. Rizzato G., Tosi G., Schiraldi G., Montemurro L., Zanni D., Sisti S. Bone protection with salmon calcitonin (sCT) in the long-term steroid therapy of chronic sarcoidosis. Sarcoidosis. 5:1988;99-103
51. Luengo M., Picado C., Del Rio L., Guanabens N., Montserrat J.M., Setoain J. Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. A 1-year follow-up study. Am. Rev. Respir. Dis. 142:1990;104-107
52. Sambrook P., Birmingham J., Kelly P., Kempler S., Nguyen T., Pocock N., et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N. Engl. J. Med. 328:1993;1747-1752
53. Healey J.H., Paget S.A., Williams-Russo P., Szatrowski T.P., Schneider R., Spiera H., et al. A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcif. Tissue Int. 58:1996;73-80
54. Ringe J.D., Welzel D. Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur. J. Clin. Pharmacol. 33:1987;35-39
55. Lems W.F., Jacobs W.G., Bijlsma J.W., Croone A., Haanen H.C., Houben H.H., et al. Effect of sodium fluoride on the prevention of corticosteroid- induced osteoporosis. Osteoporos. Int. 7:1997;575-582
56. Lems W.F., Jacobs J.W., Bijlsma J.W., van Veen G.J., Houben H.H., Haanen H.C., et al. Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis? Ann. Rheum. Dis. 56:1997;357-363
57. Guaydier-Souquieres G., Kotzki P.O., Sabatier J.P., Basse-Cathalinat B., Loeb G. In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study. Osteoporos. Int. 6:1996;171-177
58. Rizzoli R., Chevalley T., Slosman D.O., Bonjour J.P. Sodium monofluorophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis. Osteoporos. Int. 5:1995;39-46
59. Lane N.E., Sanchez S., Modin G.W., Genant H.K., Pierini E., Arnaud C.D. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J. Clin. Invest. 102:1998;1627-1633
60. Reid I.R., Wattie D.J., Evans M.C., Stapleton J.P. Testosterone therapy in glucocorticoid-treated men. Arch. Intern. Med. 156:1996;1173-1177
61. Adami S., Fossaluzza V., Rossini M., Bertoldo F., Gatti D., Zamberlan N., et al. The prevention of corticosteroid-induced osteoporosis with nandrolone decanoate. Bone Miner. 15:1991;73-81
62. Eastell R., Reid D.M., Compston J., Cooper C., Fogelman I., Francis R.M., et al. A UK consensus group on management of glucocorticoid-induced osteoporosis: an update. J. Intern. Med. 244:1998;271-292
63. Buckley L.M., Leib E.S., Cartularo K.S., Vacek P.M., Cooper S.M. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 125:1996;961-968
64. Bernstein C.N., Seeger L.L., Anton P.A., Artinian L., Geffrey S., Goodman W., et al. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol. Ther. 10:1996;777-786
65. Bijlsma J.W., Raymakers J.A., Mosch C., Hoekstra A., Derksen R.H., Baart D.L.F., et al. Effect of oral calcium and vitamin D on glucocorticoid-induced osteopenia. Clin. Exp. Rheumatol. 6:1988;113-119
66. Dykman T.R., Haralson K.M., Gluck O.S., Murphy W.A., Teitelbaum S.L., Hahn T.J., et al. Effect of oral 1, 2, 5-dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum. 27:1984;1336-1343
67. Amin S., LaValley M.P., Simms R.W., Felson D.T. The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum. 42:1999;1740-1751
68. Wolfhagen F.H., van Buuren H.R., den Ouden J.W., Hop W.C., van Leeuwen J.P., Schalm S.W., et al. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study. J. Hepatol. 26:1997;325-330
69. Jenkins E.A., Walker-Bone K.E., Wood A., McCrae F.C., Cooper C., Cawley M.I. The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate. Scand. J. Rheumatol. 28:1999;152-156
70. Nordborg E., Schaufelberger C., Andersson R., Bosaeus I., Bengtsson B.A. The ineffectiveness of cyclical oral clodronate on bone mineral density in glucocorticoid-treated patients with giant-cell arteritis. J. Intern. Med. 242:1997;367-371
71. Worth H., Stammen D., Keck E. Therapy of steroid-induced bone loss in adult asthmatics with calcium, vitamin D, and a diphosphonate. Am. J. Respir. Crit. Care Med. 150:1994;394-397
72. Adachi J.D., Bensen W.G., Bell M.J., Bianchi F.A., Cividino A.A., Craig G.L., et al. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br. J. Rheumatol. 36:1997;255-259
73. Kotaniemi A., Piirainen H., Paimela L., Leirisalo-Repo M., Uoti-Reilama K., Lahdentausta P., et al. Is continuous intranasal salmon calcitonin effective in treating axial bone loss in patients with active rheumatoid arthritis receiving low dose glucocorticoid therapy? J. Rheumatol. 23:1996;1875-1879
74. Luengo M., Pons F., Martinez de Osaba M.J., Picado C. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a 2 year follow up study. Thorax. 49:1994;1099-1102
75. Brown J.P., Josse R.G. Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. 167:2002;S1-S34
76. Recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis: 2001 update, American College of Rheumatology Ad Hoc Committee on Glucocoritcoid-Induced Osteoporosis, Arthritis Rheum. 44 (2001) 1496-503.